<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262466</url>
  </required_header>
  <id_info>
    <org_study_id>IMC-F106C-101</org_study_id>
    <nct_id>NCT04262466</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors</brief_title>
  <official_title>Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunocore Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC Â®) designed for the&#xD;
      treatment of cancers positive for the tumor-associated antigen PRAME. This is a&#xD;
      first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult&#xD;
      patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMC-F106C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable&#xD;
      tumors which include select Advanced Solid Tumors and will be conducted in two phases.&#xD;
&#xD;
        1. Phase 1: To identify the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 dose&#xD;
           (RP2D) of IMC-F106C as a single agent (Arm A) and administered in combination with&#xD;
           Checkpoint Inhibitors (Arm B).&#xD;
&#xD;
        2. Phase 2: To assess the preliminary anti-tumor activity of IMC-F106C as a single agent&#xD;
           administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of Dose-limiting toxicity (DLT)s</measure>
    <time_frame>From first dose to DLT period (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in vital signs</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from baseline will be summarized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated for up to 12 months)</time_frame>
    <description>Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to adverse event Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to treatment-related adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Best Overall Response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C AUC will be assessed for ~3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C Cmax will be assessed for ~3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C Tmax will be assessed for ~3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The elimination half-life (t1/2)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C t1/2 will be assessed for ~ 3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-IMC-F106C antibody formation</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte counts over time</measure>
    <time_frame>approximately 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum cytokines over time</measure>
    <time_frame>approximately 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Select Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMC-F106C - Arm A - Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-F106C - Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-F106C</intervention_name>
    <description>Weekly IV Infusions</description>
    <arm_group_label>IMC-F106C - Arm A - Phase 1</arm_group_label>
    <arm_group_label>IMC-F106C - Phase 2</arm_group_label>
    <arm_group_label>IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD(L)1</intervention_name>
    <description>Every 3 weeks</description>
    <arm_group_label>IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG PS 0 or 1&#xD;
&#xD;
          2. HLA-A*02:01 positive&#xD;
&#xD;
          3. PRAME positive tumor&#xD;
&#xD;
          4. Relapsed from, refractory to, or intolerant of standard therapy&#xD;
&#xD;
          5. If applicable, must agree to use highly effective contraception&#xD;
&#xD;
          6. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the Informed Consent (ICF) and protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic or untreated central nervous system metastasis&#xD;
&#xD;
          2. Recent bowel obstruction&#xD;
&#xD;
          3. Ascites requiring recurrent paracentesis&#xD;
&#xD;
          4. Significant immune-mediated adverse event with prior immunotherapy (patients in&#xD;
             combination treatment)&#xD;
&#xD;
          5. Inadequate washout from prior anticancer therapy&#xD;
&#xD;
          6. Significant ongoing toxicity from prior anticancer treatment&#xD;
&#xD;
          7. Out-of-range laboratory values&#xD;
&#xD;
          8. Clinically significant medical condition&#xD;
&#xD;
          9. Ongoing requirement for immunosuppressive treatment&#xD;
&#xD;
         10. Prior solid organ or bone marrow transplant&#xD;
&#xD;
         11. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection&#xD;
&#xD;
         12. Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
         13. Significant secondary malignancy&#xD;
&#xD;
         14. Hypersensitivity to study drug or excipients&#xD;
&#xD;
         15. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study&#xD;
             intervention&#xD;
&#xD;
         16. Pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaad Abdullah, MD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Immunocore Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaad E Abdullah, MD, FACP</last_name>
    <phone>484-534-5261</phone>
    <email>clinicaltrials@immunocore.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed Dar</last_name>
    <phone>1-844-466-8661</phone>
    <email>clinicaltrials@immunocore.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Menendez</last_name>
    </contact>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Molnar</last_name>
    </contact>
    <contact_backup>
      <last_name>Frances Lara</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hui Amy Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Mistretta</last_name>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Vann</last_name>
    </contact_backup>
    <investigator>
      <last_name>Emerson Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Smith</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Hellman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Homan</last_name>
    </contact>
    <contact_backup>
      <last_name>Kiersten During</last_name>
    </contact_backup>
    <investigator>
      <last_name>Raid Aljumaily, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrine Senter</last_name>
    </contact>
    <contact_backup>
      <last_name>Taylor Holton</last_name>
    </contact_backup>
    <investigator>
      <last_name>Takami Sato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brodeur</last_name>
    </contact>
    <investigator>
      <last_name>Diwakar Davar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Burroughs</last_name>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeane Painter</last_name>
    </contact>
    <contact_backup>
      <last_name>Jessica Catrett</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ectaerina Dumbrava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>City Of London</state>
        <zip>W1G6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Victoria Borja Beral</last_name>
    </contact>
    <contact_backup>
      <last_name>Juan Pedro Navarro Garcia</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital London</name>
      <address>
        <city>London</city>
        <zip>W1T7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shazia Begum</last_name>
    </contact>
    <investigator>
      <last_name>Heather Shaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ritchie</last_name>
    </contact>
    <contact_backup>
      <last_name>Schweta Vyas</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fiona Thistlethwaite</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Surrey Quays</city>
        <zip>SM25PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Bar</last_name>
    </contact>
    <contact_backup>
      <last_name>Mahesha Ganegoda</last_name>
    </contact_backup>
    <investigator>
      <last_name>Juanita Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ImmTAC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Bispecific T cell receptor fusion protein</keyword>
  <keyword>Immune mobilizing monoclonal T cell receptor against cancer</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>PD1 / PD-1</keyword>
  <keyword>PD-L1 / PDL1</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

